Developer docs
API playgroundTry for free, no card

Search company profiles

OptiNose

Full company profile

uuid00046jp

Namestring
OptiNose
Legal namestring
OptiNose US, Inc.
Websiteurl
optinose.com
Company typeenum
Private
Founded yearint
2000
Descriptiontext

OptiNose US, Inc. is a U.S.-domiciled specialty pharmaceutical company that develops and commercializes prescription treatments for diseases managed by ear, nose, and throat (ENT) and allergy specialists, with its worldwide headquarters in Yardley, Pennsylvania. The company's core technology is its patented Bi-Directional Exhalation Delivery System (EDS), a drug-device combination platform available in liquid and powder configurations that uses patient exhalation to seal the soft palate and propel medication high and deep into the nasal passages, reaching anatomical sites beyond the nasal valve that conventional nasal sprays cannot effectively penetrate. The platform also has potential applications in nose-to-brain drug delivery for central nervous system disorders.

The company monetizes this platform primarily through direct commercialization of its lead product XHANCE (fluticasone propionate), FDA-approved in September 2017 for nasal polyps and in March 2024 for chronic sinusitis, sold through a network of seven authorized pharmaceutical wholesalers to ENT and allergy specialists with a planned expansion into primary care. A second product, ONZETRA Xsail (sumatriptan nasal powder) for acute migraine, was out-licensed to Currax Pharmaceuticals in September 2019 for commercialization in the United States, Canada, and Mexico, generating royalty and licensing revenue. The company additionally pursues technology licensing arrangements with selected pharmaceutical and biotechnology partners developing CNS, systemic, or topical nasal compounds.

Short descriptiontext

OptiNose is a U.S. specialty pharmaceutical company that develops and commercializes prescription nasal treatments using its proprietary Bi-Directional Exhalation Delivery System (EDS), serving ENT/allergy specialists and chronic rhinosinusitis patients with its lead product XHANCE.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersYardley, United States
HQ citystring
Yardley
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
nasal drug delivery, specialty pharmaceuticals, ENT treatments, prescription nasal sprays, drug-device combinations
Industry3 codes
PRIMARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Surgical & Medical Instruments & Apparatus3841
Product category
Specialty Pharmaceuticals - Nasal Drug Delivery
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Product Sales - XHANCE
TypeOne Time License
Description

Revenue from sales of FDA-approved prescription treatment XHANCE (fluticasone propionate) for nasal polyps and chronic sinusitis, commercialized directly by the company to ENT and allergy specialists.

optinose.com
2Licensing Revenue - ONZETRA
TypeLicensing Royalties
Description

Royalty and licensing revenue from Currax Pharmaceuticals for ONZETRA Xsail (sumatriptan nasal powder) in US, Canada, and Mexico under September 2019 License Agreement.

optinose.com
3Technology Licensing
TypeLicensing Royalties
Description

Optinose has entered into technology licensing arrangements with carefully selected companies developing products that may benefit from the unique Optinose delivery technology, including use by academic researchers.

optinose.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Marketing or Sales, Technology or R&D, Supply Chain, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1XHANCE
Description

FDA-approved prescription treatment for nasal polyps and chronic sinusitis, delivered using OptiNose's Bi-Directional Exhalation Delivery System.

optinose.com
+2 more records
Core offering1 text field

OptiNose develops and commercializes prescription drug-device combination products for ear, nose, and throat conditions, built on its proprietary Bi-Directional Exhalation Delivery System (EDS). Its core product XHANCE (fluticasone propionate) is FDA-approved for nasal polyps and chronic sinusitis, while ONZETRA Xsail (sumatriptan nasal powder) for acute migraine is licensed to Currax Pharmaceuticals. The EDS platform is also licensed to other pharmaceutical partners for additional therapeutic applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Significantly larger initial deposition in upper and middle posterior nasal regions compared to traditional spray (53.5% vs 15.7%, p<0.02)
+3 more records
Product overview1 text field

OptiNose is a specialty pharmaceutical company offering a portfolio of prescription nasal spray products powered by its proprietary Bi-Directional Exhalation Delivery System (EDS) technology. The core product portfolio consists of XHANCE (fluticasone propionate), an FDA-approved treatment for nasal polyps and chronic sinusitis, and ONZETRA Xsail (sumatriptan nasal powder), licensed to Currax Pharmaceuticals for migraine treatment. The EDS platform serves as the foundational technology enabling both products to deliver medication deep into nasal passages, and is also being evaluated for potential nose-to-brain drug delivery applications.

Product and service3 records
1XHANCE (fluticasone propionate)
CategoryPrescription Pharmaceutical - ENT/Allergy
Description

FDA-approved prescription nasal spray delivering fluticasone propionate deep into nasal passages via the Bi-Directional Exhalation Delivery System. Indicated for the treatment of nasal polyps in adults (since September 2017) and chronic sinusitis in adults (since March 2024). Commercialized directly by OptiNose to ENT and allergy specialists.

2ONZETRA Xsail (sumatriptan nasal powder)
CategoryPrescription Pharmaceutical - Neurology/Migraine
Description

Low-dose sumatriptan nasal powder delivered via OptiNose's Bi-Directional Exhalation Delivery System for acute treatment of migraine with or without aura in adults. Licensed exclusively to Currax Pharmaceuticals for US, Canada, and Mexico.

3Bi-Directional Exhalation Delivery Systems (EDS) Technology Platform
CategoryDrug Delivery Technology Platform - Licensing
Description

Proprietary drug-device delivery technology platform that uses patient exhalation to create an airtight seal of the soft palate and propel medication beyond the nasal valve into deep nasal passages. Available in liquid and powder configurations, it is licensed to selected pharmaceutical, biotechnology, and academic partners for CNS, systemic, and topical nasal applications, including potential nose-to-brain drug delivery.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2019-09-01
Description

In September 2019, Optinose announced a License Agreement with Currax Pharmaceuticals granting exclusive rights to certain Optinose intellectual property for marketing ONZETRA Xsail (sumatriptan nasal powder) in the United States, Canada, and Mexico. This partnership enabled commercialization of the migraine treatment through Currax's existing commercial infrastructure.

2Academic Researchers
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Optinose has allowed use of its technology by a small number of academic researchers for scientific studies and clinical trials investigating nasal drug delivery applications.

optinose.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Optinose has entered into technology licensing arrangements with carefully selected companies developing products that may benefit greatly from the unique Optinose delivery technology for CNS, systemic, or topical nasal compounds.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Paratek acquired Optinose in March 2025 for up to $330 million ($9 per share upfront plus CVRs). The acquisition was triggered by XHANCE's 2023 FDA label expansion broadening eligible patient population 10-fold to 10 million people, enabling Paratek to commercialize the product through its existing primary care sales force.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage ENT specialty pharmaceutical company developing drug-delivery technologies for chronic rhinosinusitis and other ENT conditions. Highly comparable to OptiNose given overlapping therapeutic focus on CRS and parallel investment in novel nasal/sinus drug delivery platforms.

TypeDirect peer
Description

Specialty pharmaceutical company developing intranasal epinephrine (neffy) for allergic reactions. Comparable to OptiNose as a small-cap intranasal drug delivery company targeting allergy/respiratory indications with novel device-enabled formulations.

TypeDirect peer
Description

Previously independent developer of steroid-eluting sinus implants (PROPEL) used by ENT surgeons in chronic rhinosinusitis patients. Directly comparable in targeting the ENT/CRS specialty prescribing base with a delivery-differentiated therapy.

4Otonomy
TypeDirect peer
Description

Specialty pharmaceutical company developing therapeutics for ear-related (otology) conditions using sustained-release drug delivery technologies. Comparable to OptiNose as a small-cap ENT-focused specialty pharma with novel drug-device combination products.

TypeBroad incumbent
Description

Global pharmaceutical company and leading manufacturer of over-the-counter and prescription nasal allergy sprays including Flonase (fluticasone). Broad incumbent competing with XHANCE in the same therapeutic class through established OTC and generic brands with massive distribution.

TypeBroad incumbent
Description

Global pharmaceutical company marketing Nasacort (triamcinolone) and other respiratory/allergy products. Broad incumbent with overlapping respiratory/allergy pharmaceutical franchise that competes for the same prescription and OTC patient pool targeted by XHANCE.

TypeBroad incumbent
Description

Global pharmaceutical company with Rhinocort (budesonide) and a broad respiratory/allergy portfolio including biologics for severe asthma and CRS. Comparable as a broad incumbent with deep respiratory franchise that overlaps with the chronic rhinosinusitis patient population.

TypeBroad incumbent
Description

Global pharmaceutical company whose respiratory portfolio includes Nasonex (mometasone) and Dulera. Broad incumbent with overlapping corticosteroid nasal spray franchise competing for the same allergy and CRS prescription patients.

TypeBroad incumbent
Description

Global generic and specialty pharmaceutical company producing generic fluticasone nasal sprays and other respiratory products. Broad incumbent that competes directly on price in the same fluticasone-based nasal spray market that XHANCE must differentiate against.

TypeEmerging player
Description

Specialty pharmaceutical company focused on injectable, inhalation, and intranasal products including generic nasal sprays. Comparable as a smaller specialty player operating in intranasal drug delivery with parallel regulatory and commercial infrastructure requirements.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OptiNose

Specialty Pharmaceuticals - Nasal Drug Deliveryoptinose.com

OptiNose is a U.S. specialty pharmaceutical company that develops and commercializes prescription nasal treatments using its proprietary Bi-Directional Exhalation Delivery System (EDS), serving ENT/allergy specialists and chronic rhinosinusitis patients with its lead product XHANCE.

What OptiNose does

OptiNose US, Inc. is a U.S.-domiciled specialty pharmaceutical company that develops and commercializes prescription treatments for diseases managed by ear, nose, and throat (ENT) and allergy specialists, with its worldwide headquarters in Yardley, Pennsylvania. The company's core technology is its patented Bi-Directional Exhalation Delivery System (EDS), a drug-device combination platform available in liquid and powder configurations that uses patient exhalation to seal the soft palate and propel medication high and deep into the nasal passages, reaching anatomical sites beyond the nasal valve that conventional nasal sprays cannot effectively penetrate. The platform also has potential applications in nose-to-brain drug delivery for central nervous system disorders.

The company monetizes this platform primarily through direct commercialization of its lead product XHANCE (fluticasone propionate), FDA-approved in September 2017 for nasal polyps and in March 2024 for chronic sinusitis, sold through a network of seven authorized pharmaceutical wholesalers to ENT and allergy specialists with a planned expansion into primary care. A second product, ONZETRA Xsail (sumatriptan nasal powder) for acute migraine, was out-licensed to Currax Pharmaceuticals in September 2019 for commercialization in the United States, Canada, and Mexico, generating royalty and licensing revenue. The company additionally pursues technology licensing arrangements with selected pharmaceutical and biotechnology partners developing CNS, systemic, or topical nasal compounds.

OptiNose firmographics

Firmographics
Name
OptiNose
Legal name
OptiNose US, Inc.
Website
https://optinose.com
Company type
Private
Founded year
2000
Operating status
Acquired
Headcount range
11–50 employees
Short description
OptiNose is a U.S. specialty pharmaceutical company that develops and commercializes prescription nasal treatments using its proprietary Bi-Directional Exhalation Delivery System (EDS), serving ENT/allergy specialists and chronic rhinosinusitis patients with its lead product XHANCE.
Ownership category
akta.pro rank

OptiNose industry classification

Industry
Product category
Specialty Pharmaceuticals - Nasal Drug Delivery
NAICS
Surgical and Medical Instrument Manufacturing (339112)
SIC
Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Nasal drug delivery
  • Specialty pharmaceuticals
  • ENT treatments
  • Prescription nasal sprays
  • Drug-device combinations

Where OptiNose is headquartered

Location

Headquarters

HQ city
Yardley
HQ country
United States
HQ region
North America

Offices1 record

Markets served

OptiNose business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Marketing or Sales, Technology or R&D, Supply Chain, Operations

Revenue model

  1. Pharmaceutical Product Sales - XHANCE: Revenue from sales of FDA-approved prescription treatment XHANCE (fluticasone propionate) for nasal polyps and chronic sinusitis, commercialized directly by the company to ENT and allergy specialists.
  2. Licensing Revenue - ONZETRA: Royalty and licensing revenue from Currax Pharmaceuticals for ONZETRA Xsail (sumatriptan nasal powder) in US, Canada, and Mexico under September 2019 License Agreement.
  3. Technology Licensing: Optinose has entered into technology licensing arrangements with carefully selected companies developing products that may benefit from the unique Optinose delivery technology, including use by academic researchers.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

OptiNose product offering

Product offering

Core offering

OptiNose develops and commercializes prescription drug-device combination products for ear, nose, and throat conditions, built on its proprietary Bi-Directional Exhalation Delivery System (EDS). Its core product XHANCE (fluticasone propionate) is FDA-approved for nasal polyps and chronic sinusitis, while ONZETRA Xsail (sumatriptan nasal powder) for acute migraine is licensed to Currax Pharmaceuticals. The EDS platform is also licensed to other pharmaceutical partners for additional therapeutic applications.

Product overview

OptiNose is a specialty pharmaceutical company offering a portfolio of prescription nasal spray products powered by its proprietary Bi-Directional Exhalation Delivery System (EDS) technology. The core product portfolio consists of XHANCE (fluticasone propionate), an FDA-approved treatment for nasal polyps and chronic sinusitis, and ONZETRA Xsail (sumatriptan nasal powder), licensed to Currax Pharmaceuticals for migraine treatment. The EDS platform serves as the foundational technology enabling both products to deliver medication deep into nasal passages, and is also being evaluated for potential nose-to-brain drug delivery applications.

Differentiator

Problem solved

Functional benefit

Brands

  • XHANCE: FDA-approved prescription treatment for nasal polyps and chronic sinusitis, delivered using OptiNose's Bi-Directional Exhalation Delivery System.
  • ONZETRA Xsail
  • Bi-Directional Exhalation Delivery Systems

Products and services

  • XHANCE (fluticasone propionate) FDA-approved prescription nasal spray delivering fluticasone propionate deep into nasal passages via the Bi-Directional Exhalation Delivery System. Indicated for the treatment of nasal polyps in adults (since September 2017) and chronic sinusitis in adults (since March 2024). Commercialized directly by OptiNose to ENT and allergy specialists.
  • ONZETRA Xsail (sumatriptan nasal powder) Low-dose sumatriptan nasal powder delivered via OptiNose's Bi-Directional Exhalation Delivery System for acute treatment of migraine with or without aura in adults. Licensed exclusively to Currax Pharmaceuticals for US, Canada, and Mexico.
  • Bi-Directional Exhalation Delivery Systems (EDS) Technology Platform Proprietary drug-device delivery technology platform that uses patient exhalation to create an airtight seal of the soft palate and propel medication beyond the nasal valve into deep nasal passages. Available in liquid and powder configurations, it is licensed to selected pharmaceutical, biotechnology, and academic partners for CNS, systemic, and topical nasal applications, including potential nose-to-brain drug delivery.

Quantifiable outcome

  • Significantly larger initial deposition in upper and middle posterior nasal regions compared to traditional spray (53.5% vs 15.7%, p<0.02)
  • +3 more outcomes

Companies that use OptiNose

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

OptiNose technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

OptiNose partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered major, minor and core.

  • Currax PharmaceuticalsmajorChannel Partner/ Reseller/ Distributor · 1 September 2019In September 2019, Optinose announced a License Agreement with Currax Pharmaceuticals granting exclusive rights to certain Optinose intellectual property for marketing ONZETRA Xsail (sumatriptan nasal powder) in the United States, Canada, and Mexico. This partnership enabled commercialization of the migraine treatment through Currax's existing commercial infrastructure.
  • Academic ResearchersminorStrategic or Co-development PartnerOptinose has allowed use of its technology by a small number of academic researchers for scientific studies and clinical trials investigating nasal drug delivery applications.
  • Pharmaceutical and Biotechnology CompaniesminorStrategic or Co-development PartnerOptinose has entered into technology licensing arrangements with carefully selected companies developing products that may benefit greatly from the unique Optinose delivery technology for CNS, systemic, or topical nasal compounds.
  • Paratek PharmaceuticalscoreStrategic or Co-development PartnerParatek acquired Optinose in March 2025 for up to $330 million ($9 per share upfront plus CVRs). The acquisition was triggered by XHANCE's 2023 FDA label expansion broadening eligible patient population 10-fold to 10 million people, enabling Paratek to commercialize the product through its existing primary care sales force.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

OptiNose competitors and assessment

Company assessment

Direct peers

  • Lyra Therapeutics: Clinical-stage ENT specialty pharmaceutical company developing drug-delivery technologies for chronic rhinosinusitis and other ENT conditions. Highly comparable to OptiNose given overlapping therapeutic focus on CRS and parallel investment in novel nasal/sinus drug delivery platforms.
  • ARS Pharmaceuticals: Specialty pharmaceutical company developing intranasal epinephrine (neffy) for allergic reactions. Comparable to OptiNose as a small-cap intranasal drug delivery company targeting allergy/respiratory indications with novel device-enabled formulations.
  • Intersect ENT (acquired by Medtronic): Previously independent developer of steroid-eluting sinus implants (PROPEL) used by ENT surgeons in chronic rhinosinusitis patients. Directly comparable in targeting the ENT/CRS specialty prescribing base with a delivery-differentiated therapy.
  • Otonomy: Specialty pharmaceutical company developing therapeutics for ear-related (otology) conditions using sustained-release drug delivery technologies. Comparable to OptiNose as a small-cap ENT-focused specialty pharma with novel drug-device combination products.

Broad incumbents

  • GlaxoSmithKline (GSK): Global pharmaceutical company and leading manufacturer of over-the-counter and prescription nasal allergy sprays including Flonase (fluticasone). Broad incumbent competing with XHANCE in the same therapeutic class through established OTC and generic brands with massive distribution.
  • Sanofi: Global pharmaceutical company marketing Nasacort (triamcinolone) and other respiratory/allergy products. Broad incumbent with overlapping respiratory/allergy pharmaceutical franchise that competes for the same prescription and OTC patient pool targeted by XHANCE.
  • AstraZeneca: Global pharmaceutical company with Rhinocort (budesonide) and a broad respiratory/allergy portfolio including biologics for severe asthma and CRS. Comparable as a broad incumbent with deep respiratory franchise that overlaps with the chronic rhinosinusitis patient population.
  • Merck & Co. Global pharmaceutical company whose respiratory portfolio includes Nasonex (mometasone) and Dulera. Broad incumbent with overlapping corticosteroid nasal spray franchise competing for the same allergy and CRS prescription patients.
  • Teva Pharmaceutical Industries: Global generic and specialty pharmaceutical company producing generic fluticasone nasal sprays and other respiratory products. Broad incumbent that competes directly on price in the same fluticasone-based nasal spray market that XHANCE must differentiate against.

Emerging players

  • Amphastar Pharmaceuticals: Specialty pharmaceutical company focused on injectable, inhalation, and intranasal products including generic nasal sprays. Comparable as a smaller specialty player operating in intranasal drug delivery with parallel regulatory and commercial infrastructure requirements.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

OptiNose social profiles

Digital presence

OptiNose compliance and trust

Trust signal

Compliance1 record

OptiNose financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OptiNose leadership team

Management profile

Number of profiles

Profiles7 records

OptiNose funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OptiNose M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OptiNose

What does OptiNose do?

OptiNose develops and commercializes prescription drug-device combination products for ear, nose, and throat conditions, built on its proprietary Bi-Directional Exhalation Delivery System (EDS). Its core product XHANCE (fluticasone propionate) is FDA-approved for nasal polyps and chronic sinusitis, while ONZETRA Xsail (sumatriptan nasal powder) for acute migraine is licensed to Currax Pharmaceuticals. The EDS platform is also licensed to other pharmaceutical partners for additional therapeutic applications.

Is OptiNose a public or private company?

OptiNose is a private company. It is classified as public and is currently acquired.

When was OptiNose founded?

OptiNose was founded in 2000. It employs 11 to 50 people.

Where is OptiNose based?

OptiNose is headquartered in Yardley, United States, in the North America region.

How does OptiNose make money?

Three revenue lines are on record. Pharmaceutical Product Sales - XHANCE is the primary driver. The others are licensing Revenue - ONZETRA and technology Licensing.

Who are OptiNose's main competitors?

Direct peers on record are Lyra Therapeutics, ARS Pharmaceuticals, Intersect ENT (acquired by Medtronic) and Otonomy. Broad incumbents are GlaxoSmithKline (GSK), Sanofi, AstraZeneca, Merck & Co. and Teva Pharmaceutical Industries. Amphastar Pharmaceuticals is listed as an emerging player.

Does OptiNose have an API?

No public API is recorded for OptiNose.

What industry is OptiNose in?

OptiNose's product category is Specialty Pharmaceuticals - Nasal Drug Delivery. Its primary akta.pro industry code is HLAIAAAH, Respiratory & Allergy Pharmaceuticals, with a secondary code of HLAHAIAK, Nasal Drug Delivery Devices (Sprays/Powder Devices). Its NAICS code is 339112 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comProjecting the Global Sinus Dilation Devices Market Size to Expand at a 9.38% CAGR Through 2032, DelveInsight AnalysisDelveInsight published a market research report projecting the global sinus dilation devices market to grow from USD 3,204.77 million in 2024 to USD 6,527.14 million by 2032, representing a CAGR of 9.38% during the forecast period. The market growth is driven by rising chronic rhinosinusitis incidence, increasing preference for minimally invasive procedures, and ongoing technological advancements. Notable recent developments include Dalent Medical's patent acquisition for its Sinusleeve device in May 2025, Optinose's FDA approval of XHANCE in March 2024, and Stryker's launch of the SinuFx Balloon Sinuplasty System in September 2023.National TodayInfluential Women: Jennifer Carothers, Global Healthcare Executive And Consultant At Global Trial PartnersJennifer Carothers is a global healthcare executive with over 30 years of experience in clinical trial operations and drug development. She has held leadership roles in companies such as Johnson & Johnson and Optinose, supporting the development of life-saving therapies. Currently, she is an independent consultant at Global Trial Management Partners, focusing on operational optimization for biopharmaceutical organizations.GlobeNewswireBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Mr. Cooper Group Inc. (Nasdaq – COOP), Beacon Roofing Supply, Inc. (Nasdaq - BECN), Optinose, Inc. (Nasdaq - OPBrodsky & Smith notified investors of investigations into four companies: Mr. Cooper, Beacon Roofing, Optinose, and Redfin. The investigations allege breach of fiduciary duties by failing to conduct a fair process, including dilution to shareholders. Contact information for attorneys is provided.GlobeNewswireBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Mr. Cooper Group Inc. (Nasdaq – COOP), Beacon Roofing Supply, Inc. (Nasdaq - BECN), Optinose, Inc. (Nasdaq - OPBrodsky & Smith notified investors of investigations into four companies: Mr. Cooper, Beacon Roofing, Optinose, and Redfin. The investigations allege breach of fiduciary duties by boards failing to conduct fair processes, including dilution and fair value concerns. Contact information for attorneys is provided.FiercePharmaParatek acquires Optinose, rhinosinusitis spray Xhance in deal worth up to $330MParatek Pharmaceuticals has acquired Optinose and its chronic rhinosinusitis nasal spray Xhance for up to $330 million in a deal structured as $9 per share upfront (a 50% premium) plus contingent value rights tied to revenue milestones. The acquisition was triggered by Xhance's 2023 FDA label expansion, which broadened the drug's eligible patient population 10-fold to 10 million people, enabling Paratek to commercialize the product through its existing primary care sales force that already calls on physicians for its antibiotic Nuzyra. Paratek, which itself was acquired in 2023 for up to $462 million by Novo Holdings and Gurnet Point, expects the deal to create a platform for future product acquisitions.BenzingaOptiNose Stock Is Soaring Today: What's Going On?Paratek Pharmaceuticals announced it will acquire OptiNose Inc for approximately $300 million, or up to $14 per share, under a definitive merger agreement. The consideration consists of $9 per share in cash plus up to $5 per share in contingent value rights tied to future commercial milestones for OptiNose's approved product XHANCE. The boards of both companies have unanimously approved the deal, which is expected to close as early as mid-2025, and Paratek says the acquisition strengthens its position as a multi-product specialty therapy company.GlobeNewswireOptinose Cancels Fourth Quarter and Full Year 2024 Earnings CallOptinose cancelled its Q4 2024 earnings call scheduled for March 20, 2025, after announcing a definitive agreement to be acquired by Paratek Pharmaceuticals. The company expects to report results for the three- and twelve-month periods ended December 31, 2024, in a timely manner.GlobeNewswireOptinose Announces Reporting Date for Fourth Quarter and Full Year 2024 Financial ResultsOptinose announced it will report fourth quarter and full-year 2024 financial results and corporate updates before market open on March 20, 2025. The company will host a conference call at 8:00 a.m. Eastern Time, with a webcast replay available for 60 days.GlobeNewswireSinusitis Pipeline Insight Analysis Report 2024: Recent Advancements and Ongoing Clinical Trials Featuring Bayer, Sanofi, and PfizerResearch and Markets added a sinusitis pipeline report covering Bayer, Sanofi, and Pfizer. The FDA approved Optinose's XHANCE nasal spray for chronic rhinosinusitis without nasal polyps, based on two Phase III trials with 554 patients. The report also profiles antibiotics like levofloxacin and moxifloxacin in development.GlobeNewswireOptinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 MillionOptinose announced preliminary unaudited Q4 2024 XHANCE net product revenue of $22.4 million, in line with prior guidance. The company estimated about 20% sequential prescription growth from Q3 to Q4 2024. Full financial results and corporate updates are expected in March.